ArticleNature2025
Human-correlated genetic models identify precision therapy for liver cancer.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Modeling human tumor evolution in mice.STAR protocols · 2026Review
- Multiscale in vivo imaging of tumor evolution using a germline conditional triple-reporter mouse.Nature biotechnology · 2026Article
- Tina: A diffusion neural network for generating personalized AI models from text prompts.Patterns (New York, N.Y.) · 2026Article
- Inhibition of Aurora B induces senescence and potentiates immunotherapy in hepatocellular carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Review
- Longitudinal Monitoring of GRIm and HCC-GRIm Scores Reveals Immunologically Relevant Prognostic Indicators in Hepatocellular Carcinoma Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs.Cancer medicine · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models.Nature reviews. Gastroenterology & hepatology · 2026Review
- Why in vivo models of disease remain indispensable.Disease models & mechanisms · 2026Article
- Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025.Cancer innovation · 2026Review
- Glyphosate-Induced Metabolic and Immune Modulation in Hepatoma Cells: Identification of Key Genes as Diagnostic and Therapeutic Targets Using an In Silico Systems Biology Approach.Journal of xenobiotics · 2026Article
- Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling.Nature genetics · 2026Article
- Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026Review
- Histological and Molecular Evaluation of Liver Biopsies: A Practical and Updated Review.International journal of molecular sciences · 2025Review
- Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening.Hepatology communications · 2025Article
- A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinoma.Disease models & mechanisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Miryam MüllerCancer Research UK Scotland Institute, Glasgow, UK. miryam_mueller@yahoo.com.ORCID 0000-0002-0751-1407
Stephanie May *Cancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-0095-7403
Holly Hall *Cancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-2779-2565
Timothy J KendallCentre for Inflammation Research, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-4174-2786
Lynn McGarryCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-7055-2615
Lauriane BlukaczDepartment of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.ORCID 0000-0002-1144-4024
Sandro NuciforoDepartment of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.ORCID 0000-0002-1863-1869
Anastasia GeorgakopoulouCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-9328-7466
Thomas JamiesonCancer Research UK Scotland Institute, Glasgow, UK.
Narisa PhinichkusolchitCancer Research UK Scotland Institute, Glasgow, UK.
Sandeep DhayadeCancer Research UK Scotland Institute, Glasgow, UK.
Toshiyasu SuzukiCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-2711-0360
Júlia Huguet-PradellLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0003-1489-356X
Ian R PowleyCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0009-0009-6079-6673
Leah Officer-JonesCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-3690-2386
Rachel L PennieCancer Research UK Scotland Institute, Glasgow, UK.
Roger Esteban-FabróLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0002-8173-3323
Albert Gris-OliverLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0003-1802-9541
Roser PinyolLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0002-0288-6314
George L SkalkaCancer Research UK Scotland Institute, Glasgow, UK.
Jack LeslieNewcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0001-6443-2396
Matthew HoareEarly Cancer Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0001-5990-9604
Joep SprangersCancer Research UK Scotland Institute, Glasgow, UK.
Gaurav MalviyaCancer Research UK Scotland Institute, Glasgow, UK.
Agata MackintoshCancer Research UK Scotland Institute, Glasgow, UK.
Emma JohnsonCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0009-0005-4362-3974
Misti McCainThe Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-1967-0421
John HalpinCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-3313-5190
Christos KiourtisCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-6682-5668
Colin NixonCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-8085-2160
Graeme ClarkCancer Research UK Scotland Institute, Glasgow, UK.
William ClarkCancer Research UK Scotland Institute, Glasgow, UK.
Robin ShawCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-5503-5233
Ann HedleyCancer Research UK Scotland Institute, Glasgow, UK.
Thomas M DrakeCancer Research UK Scotland Institute, Glasgow, UK.
Ee Hong TanCancer Research UK Scotland Institute, Glasgow, UK.
Matt NeilsonCancer Research UK Scotland Institute, Glasgow, UK.
Daniel J MurphyCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-5538-5468
David Y LewisCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-9329-1326
Helen L ReevesThe Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0003-0359-9795
John Le QuesneCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-3552-7446
Derek A MannNewcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0003-0950-243X
Leo M CarlinCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-7172-5234
Karen BlythCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-9304-439X
Josep M LlovetLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Markus H HeimDepartment of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.ORCID 0000-0002-7523-4894
Owen J SansomCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-9540-3010
Crispin J MillerCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-4341-1283
Thomas G BirdCancer Research UK Scotland Institute, Glasgow, UK. t.bird@crukscotlandinstitute.ac.uk.ORCID 0000-0002-6120-1581
Funding
The Role of KLF6 in Hepatic FibrosisR01DK056621 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FRIEDMAN, SCOTT L. · 2000 to 2019
$6.2MHepatic stellate cells in NASH fibrosis and HCCR01DK128289 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT L. FRIEDMAN · 2021 to 2026
$2.6MDeterminants of immunotherapy response in NASH-Hepatocellular carcinomaR01CA273932 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JOSEP M LLOVET · 2023 to 2026
$2.0MNCI NIH HHS R01 CA273932NIDDK NIH HHS R01 DK056621NIDDK NIH HHS R01 DK128289Wellcome Trust
Abstract
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is a leading cause of cancer-related mortality worldwide
Indexed as
Carcinoma, HepatocellularLiver NeoplasmsModels, GeneticPrecision MedicineAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMaleMiceMutationTranscriptome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.